ArticlePharmaceuticals (Basel, Switzerland)2024

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study.

Teppei Hagino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.